Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trials
Solange Peters(University Hospital of Lausanne), Mary O’Brien(Royal Marsden NHS Foundation Trust), F. Bustin(Centre hospitalier régional de la Citadelle), Rolf A. Stahel(International Breast Cancer Study Group), Veerle Surmont(Ghent University Hospital), Heidi Roschitzki‐Voser, Amina Scherz(University of Bern), Dunson Ejedepang(European Organisation for Research and Treatment of Cancer), M. Guillot, Hoi-Shen Radcliffe(Amgen (United States)), Isidoro Barneto Aranda(Hospital Universitario Reina Sofía), Zoi Tsourti(Frontier Science Foundation-Hellas), Jacky Créquit(Centre Hospitalier de Beauvais), Sarah Danson(Weston Park Cancer Centre), Alessia Pochesci(European Organisation for Research and Treatment of Cancer), Deirdre O’Mahony(Bon Secours Hospital Cork), Urania Dafni(Frontier Science Foundation-Hellas), Jakob Rudzki, Linda Coate(University Health Network), Gaston Demonty(Amgen (Belgium)), Baktiar Hasan(Heidelberg University), Daniel Rauch(Washington University in St. Louis)
Cited by 9
Related Papers
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k